Form 4: Acrivon Therapeutics Executives Report Changes in Beneficial Ownership
SEC Form 4 Filing
Acrivon Therapeutics' CEO and EVP report changes in their beneficial ownership of common stock due to tax withholding upon vesting of restricted stock units.
Summary
- Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, and Kristina Masson, EVP, reported changes in their beneficial ownership of the company's common stock.
- The changes are due to shares withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units on August 21, 2024.
- Blume-Jensen disposed of shares at a price of $9.19.
- After the transaction, Blume-Jensen directly owns 2,422,513 shares of common stock and indirectly owns 317,246 shares.
- Masson indirectly owns 317,246 shares.
- The report was filed on August 23, 2024.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. This filing indicates routine tax-related transactions.
Key Dates
| Date | Description |
|---|---|
| 08/21/2024 | Date of transaction (shares withheld for tax obligations). |
| 08/23/2024 | Date of filing the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.